hCG vs Kisspeptin-10

Glycoprotein hormone binding LH receptor on Leydig cells; stimulates testosterone production; prevents testicular atrophy during TRT; maintains spermatogenesis via FSH-like activity

Human chorionic gonadotropin (hCG) is a glycoprotein hormone that acts as a functional analogue of luteinizing hormone (LH), binding to LH receptors on Leydig cells in the testes and granulosa cells in the ovaries to stimulate steroidogenesis. In men, hCG stimulates testicular testosterone production directly, making it a widely used clinical tool for hypogonadotropic hypogonadism, male fertility support, and preservation of testicular function alongside testosterone replacement therapy. Clinical research demonstrates hCG effectiveness for improving testosterone levels and sperm parameters in males with gonadotropin deficiency, as well as for triggering final oocyte maturation in IVF protocols. hCG is an FDA-regulated biologic available in multiple approved formulations; use requires physician supervision due to dose-dependent effects on testosterone, estradiol, and reproductive signaling. hCG dosage in TRT support: in men using testosterone replacement therapy, hCG is prescribed to prevent testicular atrophy and maintain intratesticular testosterone levels needed for spermatogenesis. Typical clinical doses range from 250 to 500 IU subcutaneously administered 2–3 times per week, though protocols vary by provider and individual response. At higher doses, hCG's stimulation of testicular testosterone can also increase aromatization to estradiol — a clinically relevant consideration in TRT management requiring estrogen monitoring. hCG vs gonadorelin: both are used in men's health for testicular preservation alongside TRT, but they act at different axis levels. hCG acts directly on Leydig cell LH receptors, bypassing the pituitary entirely — a direct trophic signal to the testes. Gonadorelin acts upstream at the pituitary to stimulate endogenous LH and FSH release, preserving the full hypothalamic-pituitary-gonadal axis including FSH-driven spermatogenesis. For men prioritizing sperm production, gonadorelin's preservation of FSH signaling offers a potential advantage; for men primarily focused on testicular volume and intratesticular testosterone maintenance, hCG provides a well-validated, direct approach. Telehealth and men's health providers offering hCG and gonadorelin protocols are listed in the PeptideBase directory.

Activates GPR54/KISS1R receptor on GnRH neurons; triggers pulsatile GnRH release → LH/FSH surge → testosterone/estrogen production

Kisspeptin-10 is a 10-amino-acid C-terminal fragment of the KISS1-derived peptide family, which serves as the primary upstream regulator of GnRH pulsatility in the hypothalamus. By binding to the KISS1R receptor on GnRH neurons, kisspeptin-10 triggers GnRH release and downstream LH and FSH secretion, positioning it as a master regulator of the reproductive neuroendocrine axis. Peer-reviewed human studies demonstrate that kisspeptin administration evokes LH pulse generation and modulates gonadotropin secretion in both healthy volunteers and individuals with reproductive dysfunction, including polycystic ovary syndrome. Kisspeptin-10 is an investigational peptide actively studied in clinical research; it is not approved by the FDA for any therapeutic indication and is not available as a licensed pharmaceutical. Kisspeptin-10 research contexts: clinical studies at Imperial College London and other institutions have characterized kisspeptin-10 pharmacology in human subjects across multiple reproductive contexts. In women, kisspeptin administration has been studied for ovulation triggering in IVF protocols as an alternative to hCG, with phase 2 trial data supporting its effectiveness for oocyte maturation while potentially reducing ovarian hyperstimulation syndrome risk. In men with hypogonadotropic hypogonadism, kisspeptin-10 infusion protocols have been studied to characterize LH pulse deficits and assess reproductive axis recovery. The peptide's upstream position in the GnRH axis — above gonadorelin, hCG, and downstream gonadotropins — makes it a research tool for understanding the root causes of hypothalamic-level reproductive dysfunction. Kisspeptin-10 vs kisspeptin-54: the two forms differ in length and pharmacokinetic profile. Kisspeptin-54 is the full 54-amino-acid peptide with a longer half-life in circulation; kisspeptin-10 is the truncated, most biologically active fragment. Human studies have used both forms depending on the research objective — kisspeptin-10 for acute LH pulse characterization, kisspeptin-54 for sustained gonadotropin studies. Neither is commercially available as an approved therapeutic. Fertility-focused telehealth providers and reproductive hormone specialists are listed in the PeptideBase directory.